
Sign up to save your podcasts
Or
In Part II of this episode, we continue to take a look back at 2019 with Dr. Andrew Cutler, as we reflect on the most FDA approvals, exciting research findings and all the important updates in psychopharmacology that could impact your practice.
Dr. Andrew Cutler is Chief Medical Officer (CMO) at the Neuroscience Education Institute (NEI). He has deeply rooted knowledge in clinical practice, academic experience, and emerging science in psychiatry through clinical trials. He is Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University and previously served as Courtesy Assistant Professor of Psychiatry at University of Florida. He has been the principal investigator on more than 400 psychiatric and medical clinical trials.
4.5
118118 ratings
In Part II of this episode, we continue to take a look back at 2019 with Dr. Andrew Cutler, as we reflect on the most FDA approvals, exciting research findings and all the important updates in psychopharmacology that could impact your practice.
Dr. Andrew Cutler is Chief Medical Officer (CMO) at the Neuroscience Education Institute (NEI). He has deeply rooted knowledge in clinical practice, academic experience, and emerging science in psychiatry through clinical trials. He is Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University and previously served as Courtesy Assistant Professor of Psychiatry at University of Florida. He has been the principal investigator on more than 400 psychiatric and medical clinical trials.
1,320 Listeners
62 Listeners
616 Listeners
1,388 Listeners
3,318 Listeners
149 Listeners
1,310 Listeners
713 Listeners
286 Listeners
343 Listeners
550 Listeners
459 Listeners
688 Listeners
155 Listeners
112 Listeners